Fed Regist. 2003 Jan 16;68(11):2339-40.
The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled "Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products." The guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). This guidance is an annex to an ICH guidance entitled "Q1A(R) Stability Testing of New Drug Substances and Products" (66 FR 56332, November 7, 2001). It is intended to provide guidance on the application of reduced designs (i.e., bracketing and matrixing) for stability studies conducted in accordance with the principles outlined in ICH Q1A(R).
美国食品药品监督管理局(FDA)宣布提供一份题为《新药原料药和制剂稳定性试验的Q1D分组和矩阵设计》的指南。该指南是在人用药品注册技术要求国际协调会议(ICH)的主持下制定的。本指南是ICH指南《Q1A(R)新药原料药和制剂的稳定性试验》(2001年11月7日,《联邦公报》第66卷,第56332页)的附件。其目的是为依据ICH Q1A(R)中概述的原则进行的稳定性研究应用简化设计(即分组和矩阵设计)提供指导。